199 related articles for article (PubMed ID: 36153564)
21. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
Else T; Giordano TJ; Hammer GD
J Clin Endocrinol Metab; 2008 Apr; 93(4):1442-9. PubMed ID: 18198226
[TBL] [Abstract][Full Text] [Related]
22. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
23. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
24. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
Hartlieb SA; Sieverling L; Nadler-Holly M; Ziehm M; Toprak UH; Herrmann C; Ishaque N; Okonechnikov K; Gartlgruber M; Park YG; Wecht EM; Savelyeva L; Henrich KO; Rosswog C; Fischer M; Hero B; Jones DTW; Pfaff E; Witt O; Pfister SM; Volckmann R; Koster J; Kiesel K; Rippe K; Taschner-Mandl S; Ambros P; Brors B; Selbach M; Feuerbach L; Westermann F
Nat Commun; 2021 Feb; 12(1):1269. PubMed ID: 33627664
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
26. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
27. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
[TBL] [Abstract][Full Text] [Related]
28. Telomerase activity in pleural malignant mesotheliomas.
Au AY; Hackl T; Yeager TR; Cohen SB; Pass HI; Harris CC; Reddel RR
Lung Cancer; 2011 Sep; 73(3):283-8. PubMed ID: 21277646
[TBL] [Abstract][Full Text] [Related]
29. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
30. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
31. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
32. Detection of alternative lengthening of telomeres mechanism on tumor sections.
Claude E; de Lhoneux G; Pierreux CE; Marbaix E; de Ville de Goyet M; Boulanger C; Van Damme A; Brichard B; Decottignies A
Mol Biomed; 2021 Oct; 2(1):32. PubMed ID: 35006465
[TBL] [Abstract][Full Text] [Related]
33. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
Duan XF; Zhao Q
J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
[TBL] [Abstract][Full Text] [Related]
34. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
35. Telomere Maintenance Mechanisms in Cancer.
Gaspar TB; Sá A; Lopes JM; Sobrinho-Simões M; Soares P; Vinagre J
Genes (Basel); 2018 May; 9(5):. PubMed ID: 29751586
[TBL] [Abstract][Full Text] [Related]
36. TRF1 phosphorylation on T271 modulates telomerase-dependent telomere length maintenance as well as the formation of ALT-associated PML bodies.
Ho A; Wilson FR; Peragine SL; Jeyanthan K; Mitchell TR; Zhu XD
Sci Rep; 2016 Nov; 6():36913. PubMed ID: 27841304
[TBL] [Abstract][Full Text] [Related]
37. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
38. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
[TBL] [Abstract][Full Text] [Related]
39. Expression of
Idilli AI; Cusanelli E; Pagani F; Berardinelli F; Bernabé M; Cayuela ML; Poliani PL; Mione MC
Front Cell Dev Biol; 2020; 8():65. PubMed ID: 32117990
[TBL] [Abstract][Full Text] [Related]
40. Amplification and Quantitation of Telomeric Extrachromosomal Circles.
Robinson NJ; Schiemann WP
Bio Protoc; 2023 Mar; 13(5):e4627. PubMed ID: 36908640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]